Approval Record: HALOPERIDOL — AJANTA PHARMA LTD, ORIG (Not disclosed in the FDA record.)

Key facts

Regulatory context

This application was reviewed under FDA's ORIG submission pathway. An Abbreviated New Drug Application (ANDA) is the FDA pathway used to approve generic drug products. Instead of repeating the clinical efficacy and safety trials already performed for the original branded product, an ANDA sponsor must demonstrate that its generic version is bioequivalent to an already-approved reference listed drug and meets the same identity, strength, quality, purity, and manufacturing standards. FDA approval of an application does not itself guarantee ongoing marketing; sponsors remain subject to post-approval manufacturing inspections and adverse-event reporting requirements. FDA publishes approval and submission records so physicians, competitors, and investors can track which sponsors and products have cleared a given regulatory pathway. An approval reflects FDA's determination on the application as submitted; any post-approval changes to manufacturing, labeling, or use typically require a separate supplemental submission.

What was approved

FDA's record shows AJANTA PHARMA LTD as the sponsor of HALOPERIDOL, with the generic name recorded as unspecified and dosage form TABLET. An Abbreviated New Drug Application (ANDA) is the FDA pathway used to approve generic drug products. Instead of repeating the clinical efficacy and safety trials already performed for the original branded product, an ANDA sponsor must demonstrate that its generic version is bioequivalent to an already-approved reference listed drug and meets the same identity, strength, quality, purity, and manufacturing standards. This specific application is submission type ORIG (submission number 1) under application number ANDA218210, with a submission status date of 20260914. FDA publishes approval and submission records so physicians, competitors, and investors can track which sponsors and products have cleared a given regulatory pathway. An approval reflects FDA's determination on the application as submitted; any post-approval changes to manufacturing, labeling, or use typically require a separate supplemental submission. This record is drawn directly from FDA's own approvals database rather than from company press materials. FDA publishes approval and submission records so physicians, competitors, and investors can track which sponsors and products have cleared a given regulatory pathway. An approval reflects FDA's determination on the application as submitted; any post-approval changes to manufacturing, labeling, or use typically require a separate supplemental submission. FDA publishes approval and submission records so physicians, competitors, and investors can track which sponsors and products have cleared a given regulatory pathway. An approval reflects FDA's determination on the application as submitted; any post-approval changes to manufacturing, labeling, or use typically require a separate supplemental submission.

Ajanta Pharma Ltd.’s FDA history

Argus HQ has recorded 4 total FDA actions tied to Ajanta Pharma Ltd.: 0 warning letters, 3 recalls, 1 approval record, and 0 Form 483 inspection citations.

Frequently asked questions

What did FDA approve?

FDA's record shows anda approval for HALOPERIDOL (unspecified), dosage form TABLET, sponsored by AJANTA PHARMA LTD, under application number ANDA218210. FDA publishes approval and submission records so physicians, competitors, and investors can track which sponsors and products have cleared a given regulatory pathway. An approval reflects FDA's determination on the application as submitted; any post-approval changes to manufacturing, labeling, or use typically require a separate supplemental submission.

What does the submission type mean?

An Abbreviated New Drug Application (ANDA) is the FDA pathway used to approve generic drug products. Instead of repeating the clinical efficacy and safety trials already performed for the original branded product, an ANDA sponsor must demonstrate that its generic version is bioequivalent to an already-approved reference listed drug and meets the same identity, strength, quality, purity, and manufacturing standards.

Is this product available now?

FDA's record lists a submission status date of 20260914. Availability, pricing, and distribution details beyond the submission status date are Not disclosed in the FDA record. FDA publishes approval and submission records so physicians, competitors, and investors can track which sponsors and products have cleared a given regulatory pathway. An approval reflects FDA's determination on the application as submitted; any post-approval changes to manufacturing, labeling, or use typically require a separate supplemental submission.

Does AJANTA PHARMA LTD have other FDA approval records?

Yes. Argus HQ has recorded 4 total FDA actions tied to AJANTA PHARMA LTD, including 1 approval record.

Related enforcement actions

• Approval (recent): ZYDUS LIFESCIENCES — ANDA approval: TRETINOIN (unspecified) →
• Approval (recent): CURIUM — NDA approval: BEXLUTRY (unspecified) →
• Approval (recent): STRIDES PHARMA — ANDA approval: MILNACIPRAN HYDROCHLORIDE (unspecified) →
• Approval (recent): MACLEODS PHARMS — ANDA approval: MILNACIPRAN HYDROCHLORIDE (unspecified) →
• Approval (recent): EMERGE BIOSCIENCE PTE. LTD. — BLA approval: GARZULYS (unspecified) →
• Approval (recent): ZYDUS LIFESCIENCES — ANDA approval: LETROZOLE (unspecified) →
• Approval (recent): DIFGEN PHARMS — ANDA approval: EPINEPHRINE (unspecified) →
• Approval (recent): AUROLIFE PHARMA LLC — ANDA approval: BECLOMETHASONE DIPROPIONATE (unspecified) →